Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co in Multiple Transactions

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co, sold a substantial number of shares in multiple transactions on June 3, 2024.

Summary

• Lilly Endowment Inc. sold shares of Eli Lilly & Co. common stock on June 3, 2024.
• The sales were executed in multiple transactions at varying prices.
• The prices ranged from $822.00 to $838.21 per share.
• A total of 176,993 shares were sold.
• Following these transactions, Lilly Endowment Inc. still holds 98,208,810 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of share sales, with no indication of positive or negative sentiment. It is a routine disclosure.

Industry Context

This Form 4 filing is a routine disclosure of share transactions by a major shareholder, and is a normal part of market activity. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders of publicly traded companies.
• The level of detail provided, including weighted average prices and price ranges, is consistent with SEC requirements for these filings.
• The transaction volume is not unusual for a large institutional investor like Lilly Endowment Inc.

Stakeholder Impact

• The share sales may have a minor impact on the stock price of Eli Lilly & Co., but the overall impact is likely to be minimal given the large number of shares outstanding.
• The transactions do not directly impact employees, customers, or suppliers.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, Form 4, securities